{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T01:31:22Z","timestamp":1794274282472,"version":"4.9.0"},"reference-count":25,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"2","license":[{"start":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T00:00:00Z","timestamp":1693440000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Tafasitamab, an anti-CD19 immunotherapy, is used with lenalidomide for patients with autologous stem cell transplant-ineligible relapsed\/refractory diffuse large B-cell lymphoma based on the results of the phase II L-MIND study (NCT02399085). We report the final 5-year analysis of this study. Eighty patients \u226518 years who had received one to three prior systemic therapies, and had Eastern Cooperative Oncology Group performance status 0-2 received up to 12 cycles of co-administered tafasitamab and lenalidomide, followed by tafasitamab monotherapy until disease progression or unacceptable toxicity. The primary endpoint was the best objective response rate. Secondary endpoints included duration of response, progression-free survival, overall survival, and safety. Exploratory analyses evaluated efficacy endpoints by prior lines of therapy. At data cutoff on November 14, 2022, the objective response rate was 57.5%, with a complete response rate of 41.3% (n=33), which was consistent with prior analyses. With a median follow-up of 44.0 months, the median duration of response was not reached. The median progression-free survival was 11.6 months (95% confidence interval [95% CI]: 5.7-45.7) with a median follow-up of 45.6 months. The median overall survival was 33.5 months (95% CI: 18.3-not reached) with a median follow-up of 65.6 months. Patients who had received one prior line of therapy (n=40) showed a higher objective response rate (67.5%; 52.5% complete responses) compared to patients who had received two or more prior lines of therapy (n=40; 47.5%; 30% complete responses), but the median duration of response was not reached in either subgroup. Other exploratory analyses revealed consistent long-term efficacy results across subgroups. Adverse events were consistent with those described in previous reports, were manageable, and their frequency decreased during tafasitamab monotherapy, with no new safety concerns. This final 5-year analysis of L-MIND demonstrates that the immunotherapy combination of tafasitamab and lenalidomide is well tolerated and has long-term clinical benefit with durable responses.<\/jats:p>","DOI":"10.3324\/haematol.2023.283480","type":"journal-article","created":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T16:12:46Z","timestamp":1693411966000},"page":"553-566","source":"Crossref","is-referenced-by-count":62,"title":["Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study"],"prefix":"10.3324","volume":"109","author":[{"given":"Johannes","family":"Duell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pau","family":"Abrisqueta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Andre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Gaidano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Gonzales-Barca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Jurczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagesh","family":"Kalakonda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Marina","family":"Liberati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kami J","family":"Maddocks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Menne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsolt","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Tournilhac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Kuffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Bakuli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aasim","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin","family":"Gurbanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,8,31]]},"reference":[{"key":"57532","unstructured":"World Health Organization. World Cancer Report: Cancer Research for Cancer Prevention. 2020."},{"key":"57533","doi-asserted-by":"crossref","unstructured":"Sarkozy C, Sehn LH. New drugs for the management of relapsed or refractory diffuse large B-cell lymphoma. Ann Lymphoma. 2019; 3:310.","DOI":"10.21037\/aol.2019.09.01"},{"key":"57534","doi-asserted-by":"crossref","unstructured":"Crump M, Neelapu SS, Farooq U. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017; 130(16):1800-1808.","DOI":"10.1182\/blood-2017-03-769620"},{"key":"57535","unstructured":"Locke F, Miklos DB, Jacobson C. Primary analysis of ZUMA 7: a phase 3 randomized trial of axicabtagene ciloleucel (axi-cel) versus standard of care therapy in patients with relapsed\/ refractory large B-cell lymphoma. Blood. 2021; 138(Suppl 1):2."},{"key":"57536","doi-asserted-by":"crossref","unstructured":"Kamdar M, Solomon SR, Arnason J. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis. Lancet. 2022; 399(10343):2294-2308.","DOI":"10.1016\/S0140-6736(22)00662-6"},{"key":"57537","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez-Barca E, Boumendil A, Blaise D. Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2020; 55(2):393-399.","DOI":"10.1038\/s41409-019-0650-x"},{"key":"57538","doi-asserted-by":"crossref","unstructured":"Sarkozy C, Coiffier B. Diffuse large B-cell lymphoma in the elderly: a review of potential difficulties. Clinical Cancer Res. 2013; 19(7):1660-1669.","DOI":"10.1158\/1078-0432.CCR-12-2837"},{"key":"57539","doi-asserted-by":"crossref","unstructured":"Gisselbrecht C, Glass B, Mounier N. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010; 28(27):4184-4190.","DOI":"10.1200\/JCO.2010.28.1618"},{"key":"57540","doi-asserted-by":"crossref","unstructured":"Chihara D, Izutsu K, Kondo E. High-dose chemotherapy with autologous stem cell transplantation for elderly patients with relapsed\/refractory diffuse large B cell lymphoma: a nationwide retrospective study. Biol Blood Marrow Transplant. 2014; 20(5):684-689.","DOI":"10.1016\/j.bbmt.2014.01.025"},{"key":"57541","doi-asserted-by":"crossref","unstructured":"Horton HM, Bernett MJ, Pong E. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res. 2008; 68(19):8049-8057.","DOI":"10.1158\/0008-5472.CAN-08-2268"},{"key":"57542","doi-asserted-by":"crossref","unstructured":"Salles G, Duell J, Gonz\u00e1lez Barca E. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020; 21(7):978-988.","DOI":"10.1016\/S1470-2045(20)30225-4"},{"key":"57543","unstructured":"MONJUVI. Prescribing information. 2020."},{"key":"57544","unstructured":"European Medicines Agency. Minjuvi, SmPC. 2022."},{"key":"57545","doi-asserted-by":"crossref","unstructured":"Duell J, Maddocks KJ, Gonz\u00e1lez-Barca E. Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. Haematologica. 2021; 106(9):2417-2426.","DOI":"10.3324\/haematol.2020.275958"},{"key":"57546","doi-asserted-by":"crossref","unstructured":"Cheson BD, Pfistner B, Juweid ME. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007; 25(5):579-586.","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"57547","doi-asserted-by":"crossref","unstructured":"Schuster SJ, Tam CS, Borchmann P. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021; 22(10):1403-1415.","DOI":"10.1016\/S1470-2045(21)00375-2"},{"key":"57548","doi-asserted-by":"crossref","unstructured":"Chong EA, Ruella M, Schuster SJ. Five-year outcomes for refractory B-cell lymphomas with CAR T-cell therapy. N Engl J Med. 2021; 384(7):673-674.","DOI":"10.1056\/NEJMc2030164"},{"key":"57549","doi-asserted-by":"crossref","unstructured":"Locke FL, Ghobadi A, Jacobson CA. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol. 2019; 20(1):31-42.","DOI":"10.1016\/S1470-2045(18)30864-7"},{"key":"57550","doi-asserted-by":"crossref","unstructured":"Neelapu SS, Jacobson CA, Ghobadi A. Five-year follow-up supports curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1). Blood. 2023; 141(19):2307-2315.","DOI":"10.1182\/blood.2022018893"},{"key":"57551","doi-asserted-by":"crossref","unstructured":"Oliai C, de Vos S. Case report: Sustained remission achieved from anti-CD19 CAR T cell therapy despite prior treatment with anti-CD19 antibody tafasitamab (MOR208) in a patient with relapsed and refractory diffuse large B-cell lymphoma. Blood. 2019; 134(Suppl 1):5360.","DOI":"10.1182\/blood-2019-129371"},{"key":"57552","doi-asserted-by":"crossref","unstructured":"ClinicalTrials.gov, Qualls D, Buege MJ, Dao P. Tafasitamab and lenalidomide in relapsed\/refractory large B cell lymphoma (R\/R LBCL): real world outcomes in a multicenter retrospective study. Blood. 2022; 140(Suppl 1):787-789.","DOI":"10.1182\/blood-2022-167620"},{"key":"57553","doi-asserted-by":"crossref","unstructured":"Belada D, Kopeckova K, Bergua Burgues JM. First-MIND: primary analysis from a phase Ib, open-label, randomized study to assess safety of tafasitamab or tafasitamab + lenalidomide in addition to R-CHOP in patients with newly diagnosed diffuse large B-cell lymphoma. Blood. 2021; 138(Suppl 1):3556.","DOI":"10.1182\/blood-2021-148354"},{"key":"57554","unstructured":"Tafasitamab + lenalidomide + R-CHOP versus R-CHOP in newly diagnosed high-intermediate and high risk DLBCL patients (frontMIND). 2023."},{"key":"57555","doi-asserted-by":"crossref","unstructured":"Galimberti S, Genuardi E, Mazziotta F. The minimal residual disease in non-Hodgkin\u2019s lymphomas: from the laboratory to the clinical practice. Front Oncol. 2019; 9:528.","DOI":"10.3389\/fonc.2019.00528"},{"key":"57556","doi-asserted-by":"crossref","unstructured":"Kurtz DM, Hogan GJ, Schultz A. Ultrasensitive MRD profiling predicts outcomes in DLBCL after frontline therapy with tafasitamab in combination with lenalidomide and R-CHOP. Blood. 2022; 140(Suppl 1):3498-3499.","DOI":"10.1182\/blood-2022-168378"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283480\/76023","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283480\/76550","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11244\/76023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:04:44Z","timestamp":1794045884000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.283480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,31]]},"references-count":25,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.283480","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,31]]}}}